Supramolecular interaction of Moxifloxacin and β-cyclodextrin spectroscopic characterization and analytical application

• Published in: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy Vol. 137; pp. 804 - 809
• Main Authors: Dsugi, Nuha Fathi Ali, Elbashir, Abdalla A.
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 25.02.2015
• Subjects: beta-Cyclodextrins - chemistry; Buffers; Chemistry, Pharmaceutical; Fluorescence spectroscopy; Fluoroquinolones - chemistry; FTIR; Hydrogen-Ion Concentration; Inclusion complex; Kinetics; Limit of Detection; Magnetic Resonance Spectroscopy; Microscopy, Electron, Scanning; Molecular Conformation; Molecular Structure; Moxifloxacin; NMR; Pharmaceutical Preparations; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Temperature; Thermodynamics; β-CD; Fluorescence spectroscopy; β-CD; NMR; Moxifloxacin; FTIR; Inclusion complex
• ISSN: 1386-1425; 1873-3557
• DOI: 10.1016/j.saa.2014.08.081

Absorbance spectra β-CD, Moxi and Moxi-β-CD Inclusion complex, concentration of Moxi 2μg/mL, β-CD2×10−4M, at room temperature, time15min, pH 8.0. [Display omitted] •Inclusion complex between Moxi and β-cyclodextrin was prepared and characterized by specrotrsopic methods.•Formation of inclusion complex 1:1 was confirmed by Job’s method.•A novel spectrofluorometric method was established for determination of Moxi in pharmaceutical formulation. The supramolecular interaction of Moxifloxacin (Moxi) and β-cyclodextrin (β-CD) has been examined by UV–VIS, FTIR, H1NMR, SEM and fluorescence spectroscopy. The formation of inclusion complex has been confirmed on the base of changes of spectroscopy properties. The results showed that β-CD reacted with Moxi to form an inclusion complex. The Moxi and β-CD complex formed a host–guest complex in 1:1 stoichiometry and inclusion constant (K=3.95×102Lmol−1) was ascertained by the typical double reciprocal plots. Furthermore, the thermodynamic parameters (ΔH°, ΔS° and ΔG°) associated with the inclusion process were also determined. Based on the significant enhancement of the fluorescence intensity of Moxi produced through complex formation, a simple, accurate, rapid and highly sensitive spectrofluorometric method for the determination of Moxi in pharmaceutical formulation was developed. The measurement of relative fluorescence intensity was carried out at 464nm with excitation at 289nm. The factors affecting the inclusion complex formation were studied and optimized. Under the optimum reaction conditions, linear relationships with good correlation coefficients (0.99973) were in the concentration range of 10–60ng/mL for spectrofluorimetry. The limit of detection (LOD) was found to be 1.6ng/mL. The proposed method was successfully applied to the analysis of Moxi in pharmaceutical preparation.